SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biop

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NAS: KERX) stock between June 1, 2009 and April 1, 2012.

For more information, click here:http://zlk.9nl.com/keryx-biopharmaceuticals-kerx/.


The complaint alleges that the Company issued materially false and misleading statements concerning the timing and success of its perifosine X-PECT Phase 3 Clinical Trial. As a result of these alleged misstatements, Keryx stock traded at artificially inflated prices. On April 2, 2012, Keryx disclosed that its Phase 3 Clinical Trial did not meet the primary endpoint of improving overall patient survival versus the drug Capecitabine and a placebo. Shares of Keryx fell from a close of $4.98 per share on March 30, 2012, to a close of $1.74 per share the following business day.

If you suffered a loss in Keryx you have until April 2, 2013to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/keryx-biopharmaceuticals-kerx/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.



Levi & Korsinsky, LLP
Joseph Levi, Esq. / Eduard Korsinsky, Esq.
212-363-7500
Toll Free: 877-363-5972
Fax: 866-367-6510
www.zlk.com

KEYWORDS:   United States  North America  New York  Pennsylvania

INDUSTRY KEYWORDS:

The article SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Goal Setting

Want to succeed? Then you need goals!

View Course »

Add a Comment

*0 / 3000 Character Maximum